

Closing the gap in the clinical adoption of computational pathology

PD Dr. Fulvia Ferrazzi
Department of Nephropathology and Institute of Pathology
Friedrich-Alexander-Universität Erlangen-Nürnberg

Learning objectives



- Understand the concepts of digital pathology and computational pathology
- Understand the challenges limiting the adoption of deep learning (DL) models in routine pathology diagnostics
- Understand the architecture and components of a standardized framework for deploying DL models in the diagnostic workflow of a fully digitized pathology department

The clinical context: histopathology



HISTOPATHOLOGY = Histos (tissue) + pathos (disease) + logos (study of)

→ "The study of diseased cells and tissues using a microscope." (NCI definition)

Histopathological glass slides




Picture from https://www.leica-microsystems.com/science-lab/industrial/hestaining-in-microscopy/


Microscopical examination




Picture from https://www.verywellhealth.com/histopathology-2252152. Credit: Hero Images / Getty Images



Gastritis



Liver inflammation



Prostate cancer

Histopathological analysis: main steps






Image credits: M. Angeloni, PhD thesis, 2025

Digital pathology workflow






Image credits: M. Angeloni, PhD thesis, 2025

Digital pathology – a practical example




pathologist's workspace

picture of FFPE material



picture of scanned slide






Caputo A et al. J Clin Pathol, 2023

Not just digitized slides, but a digitized pathology department




Eloy et al., Digital transformation of pathology - the European Society of Pathology expert opinion paper, Virchows Archiv, 2025




Computational pathology





From WSIs to deep-learning models
















From WSIs to deep-learning models





From WSIs to deep-learning models





Patch-level vs slide-level predictions




Patch-level

(strongly supervised)

Slide-level

(weakly supervised)




DL prediction of upper trait urothelial carcinoma (UTUC) protein-based subtypes



Hierarchical clustering to identify UTUC subtypes

N = 163 invasive UTUC samples (pT1+)



Angeloni,..., Ferrazzi*, Bahlinger*, J Pathol Clin Res, 2024

13

DL prediction of upper trait urothelial carcinoma (UTUC) protein-based subtypes



Hierarchical clustering to identify UTUC subtypes

Expression

N = 163 invasive UTUC samples (pT1+) Basal markers CD44 CK5 CK14 Luminal markers FOXA1 GATA3 GATA3

CK20

CD44


CK5

CK14

Basal

Subtype •

UTUC subtypes prediction from H&E slides




Angeloni,..., Ferrazzi*, Bahlinger*, J Pathol Clin Res, 2024

Increasing number of computational models in pathology




PubMed search: ("computational pathology" OR "digital pathology" OR "whole slide imag*") AND ("artificial intelligence" OR "machine learning" OR "deep learning" OR "image analysis") – last update: 29/09/2025



Computational pathology's impact



Prediction of molecular biomarkers



Prediction of immunotherapy response

Research

JAMA Oncology | Original Investigation

Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer

Mehrdad Rakaee, PhD; Masoud Tafavvoghi, MSc; Biagio Ricciuti, MD; Joao V. Alessi, MD; Alessio Cortellini, MD, PhD; Fabrizio Citarella, MD; Lorenzo Nibid, MD; Giuseppe Perrone, MD; Elio Adib, MD; Claudia A. M. Fulgenzi, MD; Cassio Murilo Hidalgo Filho, MD; Alessandro Di Federico, MD; Falah Jabar, PhD; Sayed Hashemi, MD; Ilias Houda, MD; Elin Richardsen, MD, PhD; Lill-Tove Rasmussen Busund, MD, PhD; Tom Donnem, MD, PhD; Idris Bahce, MD, PhD; David J. Pinato, MD, PhD; Åslaug Helland, MD, PhD; Lynette M. Sholl, MD; Mark M. Awad, MD, PhD; David J. Kwiatkowski, MD, PhD

JAMA Oncol. 2025;11(2):109-118. doi:10.1001/jamaoncol.2024.5356 Published online December 26, 2024.


Limited application of DL models in routine pathology practice



- A fully digital workflow is required
- Lack of prospective clinical validation and required regulatory approval for clinical use of Al-based assays
- Lack of/limited reimbursement for AI use
- Missing protocol for the integration of computational pathology solutions
- Difficulty in re-using publicly available DL models
- Black-box nature of Al tools

Closing the gap in the clinical adoption of computational pathology






HL7-based integration framework scheme




- portable and standardized integration framework
- inclusion of publicly available and custom developed DL models
- implementation of intuitive visualization strategies




Request: laboratory order message (OML^O33) from AP-LIS to AI-DSS





Request: laboratory order message (OML^O33) from AP-LIS to AI-DSS





- default-mode: correspondence table between tissue type, staining and DL models
- on-demand: drop-down menu in AP-LIS

MSH|^~\&|ZZZ|WWW|XXX|YYYY|20240322080152||OML^O33^OML_O33|2857198947|P|2.6

PID|||PRVPRV43S04A075M^^^CF~153042^^^^MPI~207444994^^^^CS||NAME^SURNAME||194

31104|F|||ADDRESS||||||||||||||

specimen SPM|1|18584052||MODEL_NAME^MODEL_NAME||||||||||notes|||20240322100000|


ORC|NW|SLIDEBARCODE|| 18-B-01806|SC||||20240322100000|||MDMMDM63M29G224V

^CLINICIAN^CLINICIAN|

observation request OBR|1|SLIDEBARCODE||HE^HE||20240322100000||||||/PATH/TO/ARCHIVE/SLIDE_ID

Results – patch-level models: unsolicited laboratory observation message (OUL^R21) from AI-DSS to AP-LIS






MSH|^~\&|XXX|YYY|ZZZ|WWW|20240322090848||OUL^R21|0001928917|P|2.6 PID|||PRVPRV43S04A075M^^^CF~153042^^^^MPI~207444994^^^^CS||NAME^SURNAME||194 31104|F|||ADDRESS|||||||||| ORC|NW|SLIDEBARCODE|| 18-B-01806|SC||||20240322100000|||MDMMDM63M29G224V **^CLINICIAN^CLINICIAN** OBR|1|SLIDEBARCODE||HE^HE||20240322100000|||||||/PATH/TO/ARCHIVE/SLIDE ID OBX|1|ST|SLIDEBARCODE^MODEL||breast-tumor-resnet34.tcga-brca|||||F name of model OBX|2|ED|SLIDEBARCODE^RUN||b'run metadata.json'|||||F metadata tissue mask OBX|3|ED|SLIDEBARCODE^MASK||b'mask.jpg'||||||F tile-level predictions OBX|4|ED|SLIDEBARCODE^TABLE||b'models_output.csv'|||||F OBX|5|ED|SLIDEBARCODE^TILE||b'tile1.jpg'|||||F OBX|6|ED|SLIDEBARCODE^TILE||b'tile2.jpg'|||||F OBX|7|ED|SLIDEBARCODE^TILE||b'tile3.jpg'|||||F OBX|8|ED|SLIDEBARCODE^TILE||b'tile4.jpg'|||||F OBX|9|ED|SLIDEBARCODE^TILE||b'tile5.jpg'|||||F

OBX: observation result segments

Results – patch-level models: unsolicited laboratory observation message (OUL^R21) from AI-DSS to AP-LIS





MSH|^~\&|XXX|YYY|ZZZ|WWW|20240322090848||OUL^R21|0001928917|P|2.6

PID|||PRVPRV43S04A075M^^^CF~153042^^^^MPI~207444994^^^^CS||NAME^SURNAME||194

31104|F|||ADDRESS||||||||||

ORC|NW|SLIDEBARCODE|| 18-B-01806|SC||||20240322100000|||MDMMDM63M29G224V

^CLINICIAN^CLINICIAN|

OBR|1|SLIDEBARCODE||HE^HE||20240322100000|||||||/PATH/TO/ARCHIVE/SLIDE ID

OBX|1|ST|SLIDEBARCODE^MODEL||breast-tumor-resnet34.tcga-brca|||||F name of model

OBX|2|ED|SLIDEBARCODE^RUN||b'run_metadata.json'|||||F

OBX|3|ED|SLIDEBARCODE^MASK||b'mask.jpg'||||||F

OBX|4|ED|SLIDEBARCODE^TABLE||b'models_output.csv'||||||F

OBX|5|ED|SLIDEBARCODE^TILE||b'tile1.jpg'||||||F

OBX|6|ED|SLIDEBARCODE^TILE||b'tile2.jpg'|||||F


OBX|7|ED|SLIDEBARCODE^TILE||b'tile3.jpg'||||||F

OBX|8|ED|SLIDEBARCODE^TILE||b'tile4.jpg'||||||F

QBX|9|ED|SLIDEBARCODE^TILE||b'tile5.jpg'|||||F

OBX: observation result segments

for binary models: top 5 predicted tiles in the LIS patient gallery



Angeloni,..., Ferrazzi*, Fraggetta*, Genome Med, 2025

Medizinische Fakultät October 7, 2025 23

metadata

tissue mask

tile-level predictions

Results – slide-level models: unsolicited laboratory observation message (OUL^R21) from AI-DSS to AP-LIS





MSH|^~\&|XXX|YYY|ZZZ|WWW|20240322090848||OUL^R21|0001928917|P|2.6

PID|||PRVPRV43S04A075M^^^CF~153042^^^^MPI~207444994^^^^CS||NAME^SURNAME||194

31104|F|||ADDRESS||||||||||

ORC|NW|SLIDEBARCODE|| 18-B-01806|SC||||20240322100000|||MDMMDM63M29G224V

^CLINICIAN^CLINICIAN|


OBR|1|SLIDEBARCODE||HE^HE||20240322100000||||||/PATH/TO/ARCHIVE/SLIDE ID

OBX|1|ST|SLIDEBARCODE^MODEL||msi-attMIL-marugoto||||||F

OBX|2|ST|SLIDEBARCODE^PRED_LABEL||isMSIH_MSIH||||||F

OBX|3|NM|SLIDEBARCODE^PRED SCORE||0.9310635||||||F

LIS virtual tray



N = 16 DL models currently integrated



 portable and standardized integration framework

inclusion of publicly available and custom developed DL models

 implementation of intuitive visualization strategies



DL models currently integrated:


- discriminate between different tissue types or conditions;
- predict the status of clinical biomarkers;
- predict the risk of cancer death.


Image created using resources from Flaticon.com

Categories of supported DL models and visualizations



- portable and standardized integration framework
- inclusion of publicly available and custom developed DL models
- implementation of intuitive visualization strategies







measurement maps binary classifiers

Categories of supported DL models and visualizations




- the establishment of an integration framework
- the inclusion of publicly available DL models
- the implementation of intuitive visualization strategies









measurement maps binary classifiers

color mapsmulti-class classifiers


Angeloni,..., Ferrazzi*, Fraggetta*, Genome Med, 2025


Categories of supported DL models and visualizations




- the establishment of an integration framework
- the inclusion of publicly available DL models
- the implementation of intuitive visualization strategies











measurement maps binary classifiers

color maps
multi-class classifiers

density maps
attention-based MIL classifiers


Angeloni,..., Ferrazzi*, Fraggetta*, Genome Med, 2025

Conclusions



Our proof-of-concept framework addressed three key challenges:

- the establishment of an integration framework
- the inclusion of publicly available and custom DL models
- the implementation of intuitive visualization strategies




Angeloni,..., Ferrazzi*, Fraggetta*, Genome Med, 2025

Conclusions



Our proof-of-concept framework addressed three key challenges:

- the establishment of an integration framework
- the inclusion of publicly available and custom DL models
- the implementation of intuitive visualization strategies



Angeloni,..., Ferrazzi*, Fraggetta*, Genome Med, 2025

LIMITATIONS:

- Research-only framework
- How to include DL-based assessment in diagnostic reports?
- Digitization of the pathology department required
- Pathologists' acceptance and AI proficiency

Acknowledgements







M. Angeloni

G. Carta

Dr. T. Dang

Dr. N. Feldker

Dr. R. Liguori

M. Sieger



Universitätsklinikum Erlangen



Nephropathology and Institute of Pathology, UKER

Prof. K. Amann Prof. A. Hartmann External/international collaborators

Dr. F. Fraggetta

and all other current and previous colleagues and collaborators!